title: [Ten year experience with ocular lymphomas and ocular adnexae lymphomas].
abstract: BACKGROUND
  Ocular lymphomas and ocular adnexae lymphomas (OL and OAL) constitute 7-8% of all extranodal lymphomas.
  
  
  OBJECTIVE
  Describe the clinical, morphologic and immunophenotypic characteristics of OAL seen in our hospital.
  
  
  METHODS
  Retrospective analysis of patient records with OL and OAL between July 1994 and July 2005. The following data was analyzed: Clinical presentation, therapy, treatment response, overall survival and disease free survival.
  
  
  RESULTS
  Ten patients with OL and OAL were identified. Of these, 8 were women and 2 men. Median age was 50. Eight of 10 patients achieved complete remission, 6 of the 6 presenting MALT Lymphoma. Two patients with stage IV had refractory disease.
  
  
  CONCLUSIONS
  In our series 0.02% of lymphomas were OL and OAL of a total 498 LNH. MALT lymphomas appear at a more advanced age, sixty percent of the cases were MALT lymphomas and were diagnosed during their early stages. Patients were followed during 21 months, global survival was 100%, free illness survival had a mean of 868 days and a survival median of 442 days.
authors.affiliation: Departamento de Hematología, Centro Médico ISSEMyM, Edo. Méx., México. roxio721110@hotmail.com
authors.forename: Rocío
authors.initials: R
authors.lastname: Caballero-Caballero
authors.forename: E Gabriela
authors.initials: EG
authors.lastname: Hernández-Rivera
authors.forename: Joseph X
authors.initials: JX
authors.lastname: López-Karpovitch
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D005134:Eye Neoplasms / Q000188:drug therapy / Q000473:pathology* / Q000532:radiotherapy; D005260:Female; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy / Q000473:pathology* / Q000532:radiotherapy; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D012189:Retrospective Studies; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents